Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth‐inhibitory and VEGF‐suppressive effects of rapamycin in leukemic cells
- 22 March 2005
- journal article
- fj express-summaries
- Published by Wiley in The FASEB Journal
- Vol. 19 (8), 960-962
- https://doi.org/10.1096/fj.04-1973fje
Abstract
The mammalian target of rapamycin (mTOR) has recently been described to be constitutively activated in Bcr-Abl-transformed cells and to mediate rapamycin-induced inhibition of growth in respective cell lines. We have recently shown that rapamycin down-regulates expression of vascular endothelial growth factor (VEGF), a mediator of leukemia-associated angiogenesis, in primary CML cells. In the present study, we analyzed growth-inhibitory in vitro and in vivo effects of rapamycin on primary CML cells and asked whether rapamycin-induced suppression of VEGF in leukemic cells is related to growth inhibition. Rapamycin dose dependently inhibited growth of primary CML cells obtained from patients with imatinib-responsive or imatinib-resistant disease as well as growth of Bcr-Abl-transformed imatinib-resistant cell lines. Moreover, we observed potent cytoreductive effects of rapamycin in a patient with imatinib-resistant Bcr-Abl+ leukemia. The growth-inhibitory effects of rapamycin on CML cells were found to be associated with G1 cell cycle arrest and with induction of apoptosis. In all cell types tested, rapamycin was found to down-regulate expression of VEGF. However, exogenously added VEGF did not counteract the rapamycin-induced decrease in proliferation. In conclusion, rapamycin inhibits growth of CML cells in vitro and in vivo and, in addition, down-regulates expression of VEGF. Both effects may contribute to the antileukemic activity of the drug in CML.Keywords
Funding Information
- Austrian Science Fund (P‐15487, P‐16412)
This publication has 50 references indexed in Scilit:
- The tor pathway: a target for cancer therapyNature Reviews Cancer, 2004
- Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKsProceedings of the National Academy of Sciences of the United States of America, 2004
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- BCR/ABL Regulates Expression of the Cyclin-dependent Kinase Inhibitor p27Kip1 through the Phosphatidylinositol 3-Kinase/AKT PathwayJournal of Biological Chemistry, 2000
- STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cellsBlood, 2000
- Blockade of the Bcr-Abl Kinase Activity Induces Apoptosis of Chronic Myelogenous Leukemia Cells by Suppressing Signal Transducer and Activator of Transcription 5–Dependent Expression of Bcl-XLThe Journal of Experimental Medicine, 2000
- The Survival Function of the Bcr-Abl Oncogene Is Mediated by Bad-Dependent and -Independent Pathways: Roles for Phosphatidylinositol 3-Kinase and RafMolecular and Cellular Biology, 2000
- Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathwayThe EMBO Journal, 1997
- A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemiaNature, 1982
- A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa StainingNature, 1973